Proteomics-based Discovery of Biomarkers for Paediatric Acute Lymphoblastic Leukaemia: Challenges and Opportunities

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2014 Jun 11

PMID 24912534

Citations 8

Authors

Elena Lopez Villar

Duojiao Wu

William C Cho

Luis Madero

Xiangdong Wang

Affiliations

Soon will be listed here.

Abstract

There are important breakthroughs in the treatment of paediatric acute lymphoblastic leukaemia (ALL) since 1950, by which the prognosis of the child majority suffered from ALL has been improved. However, there are urgent needs to have disease-specific biomarkers to monitor the therapeutic efficacy and predict the patient prognosis. The present study overviewed proteomics-based research on paediatric ALL to discuss important advances to combat cancer cells and search novel and real protein biomarkers of resistance or sensitivity to drugs which target the signalling networks. We highlighted the importance and significance of a proper phospho-quantitative design and strategy for paediatric ALL between relapse and remission, when human body fluids from cerebrospinal, peripheral blood, or bone-marrow were applied. The present article also assessed the schedule for the analysis of body fluids from patients at different states, importance of proteomics-based tools to discover ALL-specific and sensitive biomarkers, to stimulate paediatric ALL research via proteomics to 'build' the reference map of the signalling networks from leukemic cells at relapse, and to monitor significant clinical therapies for ALL-relapse.

Citing Articles

Application of Omics Analyses in Pediatric B-Cell Acute Lymphoblastic Leukemia.

Vllahu M, Savarese M, Cantiello I, Munno C, Sarcina R, Stellato P Biomedicines. 2025; 13(2).

PMID: 40002837 PMC: 11852417. DOI: 10.3390/biomedicines13020424.

Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine.

Sun K, Wong Y, Cheung K, Yuen C, Chan Y, Lai W Diagnostics (Basel). 2022; 12(2).

PMID: 35204500 PMC: 8871212. DOI: 10.3390/diagnostics12020409.

Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance.

Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L Cancers (Basel). 2020; 12(2).

PMID: 32098410 PMC: 7072684. DOI: 10.3390/cancers12020512.

Drug Resistance Biomarkers and Their Clinical Applications in Childhood Acute Lymphoblastic Leukemia.

Aberuyi N, Rahgozar S, Ghodousi E, Ghaedi K Front Oncol. 2020; 9:1496.

PMID: 32010613 PMC: 6978753. DOI: 10.3389/fonc.2019.01496.

Proteomic analysis of cerebrospinal fluid in pediatric acute lymphoblastic leukemia patients: a pilot study.

Guo L, Ren H, Zeng H, Gong Y, Ma X Onco Targets Ther. 2019; 12:3859-3868.

PMID: 31190885 PMC: 6527054. DOI: 10.2147/OTT.S193616.

References

Cho W . Emerging techniques in molecular detection of circulating tumor cells. Expert Rev Mol Diagn. 2014; 14(2):131-4. DOI: 10.1586/14737159.2014.868308. View

Zheng J, Dong S, Wang Q, Pan J, Chen S, Qiu H . [Deletions and rearrangements of PAX5 gene in B-lineage acute lymphoblastic leukemia]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2013; 30(5):549-52. DOI: 10.3760/cma.j.issn.1003-9406.2013.05.009. View

Hu J, Lin M, Liu T, Li J, Chen B, Chen Y . DIGE-based proteomic analysis identifies nucleophosmin/B23 and nucleolin C23 as over-expressed proteins in relapsed/refractory acute leukemia. Leuk Res. 2011; 35(8):1087-92. DOI: 10.1016/j.leukres.2011.01.010. View

Thingholm T, Jensen O, Robinson P, Larsen M . SIMAC (sequential elution from IMAC), a phosphoproteomics strategy for the rapid separation of monophosphorylated from multiply phosphorylated peptides. Mol Cell Proteomics. 2007; 7(4):661-71. DOI: 10.1074/mcp.M700362-MCP200. View

Kumagai M, Manabe A, Coustan-Smith E, Blakley R, Beck W, Santana V . Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs. II. Potent cytotoxicity of 2-chloro-deoxyadenosine in acute lymphoblastic leukemia. Leukemia. 1994; 8(7):1116-23. View

Szczepanek J, Styczynski J, Haus O, Tretyn A, Wysocki M . Relapse of acute lymphoblastic leukemia in children in the context of microarray analyses. Arch Immunol Ther Exp (Warsz). 2011; 59(1):61-8. DOI: 10.1007/s00005-010-0110-1. View

Ghosh P, Whitehouse M . Potential antileukemic and immunosuppressive drugs. Preparation and in vitro pharmacological acitivity of some benzo-2,1,3-oxadiazoles (benzofurazans) and their N-oxides (benzofuroxans). J Med Chem. 1968; 11(2):305-11. DOI: 10.1021/jm00308a027. View

Shi L, Zhang J, Wu P, Feng K, Li J, Xie Z . Discovery and identification of potential biomarkers of pediatric acute lymphoblastic leukemia. Proteome Sci. 2009; 7:7. PMC: 2662805. DOI: 10.1186/1477-5956-7-7. View

Papaemmanuil E, Rapado I, Li Y, Potter N, Wedge D, Tubio J . RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet. 2014; 46(2):116-25. PMC: 3960636. DOI: 10.1038/ng.2874. View

10.

Takeuchi M, Katayama Y, Okamura A, Yamamoto K, Shimoyama M, Matsui T . Chronic myeloid leukemia with a rare variant BCR-ABL translocation: t(9;22;21)(q34;q11.2;q11.2). Cancer Genet Cytogenet. 2007; 179(1):85-7. DOI: 10.1016/j.cancergencyto.2007.08.010. View

11.

Vakana E, Arslan A, Szilard A, Altman J, Platanias L . Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells. PLoS One. 2013; 8(11):e78780. PMC: 3832611. DOI: 10.1371/journal.pone.0078780. View

12.

Trimpin S, Wang B, Lietz C, Marshall D, Richards A, Inutan E . New ionization processes and applications for use in mass spectrometry. Crit Rev Biochem Mol Biol. 2013; 48(5):409-29. DOI: 10.3109/10409238.2013.806887. View

13.

Al Achkar W, Wafa A, Ali B, Manvelyan M, Liehr T . A rare chronic myeloid leukemia case with Philadelphia chromosome, BCR-ABL e13a3 transcript and complex translocation involving four different chromosomes. Oncol Lett. 2012; 1(5):797-800. PMC: 3436393. DOI: 10.3892/ol_00000139. View

14.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

15.

Pizzirani D, Roberti M, Grimaudo S, Di Cristina A, Pipitone R, Tolomeo M . Identification of biphenyl-based hybrid molecules able to decrease the intracellular level of Bcl-2 protein in Bcl-2 overexpressing leukemia cells. J Med Chem. 2009; 52(21):6936-40. DOI: 10.1021/jm900907s. View

16.

Bennour A, Sennana H, Laatiri M, Khelif A, Saad A . A masked BCR/ABL rearrangement in a case of chronic myeloid leukemia with translocation t(3;9)(p14;q34). Cancer Genet Cytogenet. 2008; 181(1):72-4. DOI: 10.1016/j.cancergencyto.2007.11.007. View

17.

Lopez E, Rodriguez Munoz S, Pascual J, Madero L . Relevant phosphoproteomic and mass spectrometry: approaches useful in clinical research. Clin Transl Med. 2013; 1(1):2. PMC: 3552569. DOI: 10.1186/2001-1326-1-2. View

18.

Perez-Andreu V, Roberts K, Harvey R, Yang W, Cheng C, Pei D . Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet. 2013; 45(12):1494-8. PMC: 4039076. DOI: 10.1038/ng.2803. View

19.

Manabe A, Yi T, Kumagai M, Campana D . Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs. I. Cytotoxicity of interferon alpha in acute lymphoblastic leukemia. Leukemia. 1993; 7(12):1990-5. View

20.

Campana D, Manabe A, Evans W . Stroma-supported immunocytometric assay (SIA): a novel method for testing the sensitivity of acute lymphoblastic leukemia cells to cytotoxic drugs. Leukemia. 1993; 7(3):482-8. View